Research
Hormonal
GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide) and dual/triple agonists induce T2D remission primarily through significant weight loss and reduction of ectopic fat, with some direct beta-cell protective effects.
If you have prediabetes or early Type 2 Diabetes and struggle with weight, GLP-1 or GLP-1/GIP agonists (like Semaglutide or Tirzepatide) are highly effective at restoring normal blood sugar levels. These drugs work by reducing appetite and body weight, with some also having direct benefits on beta-cells. They are often used alongside lifestyle changes.
StrongSupportsVERY_HIGH confidence
Recently, the therapeutic armamentarium in the field of diabetology has been enriched with new antihyperglycemic drugs with considerable efficacy in reducing body weight, which could play a pathogenetic role in the remission of T2D, not through the classical incretin effect, but by improving adipose tissue functions.
Why this rating
Supported by multiple large RCTs (STEP, SCALE, SURMOUNT).
Source
Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Danila Capoccia et al. · Acta Diabetologica · 2024
narrative_reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →